Oncolytic adenovirus treatment of a patient with refractory neuroblastoma

Sari Pesonen Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland

Heikki Helin HUSLAB, Helsinki University Central Hospital, Finland; Department of Pathology, Helsinki University Central Hospital, Finland

Petri Nokisalmi Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland

Sophie Escutenaire Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland

Camilla Ribacka Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland

Merja Sarkioja Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland

Vincenzo Cerullo Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland

Kilian Guse Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland

Gerd Bauerschmitz Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland; Department of Obstetrics and Gynecology, Duesseldorf University Medical Center, Heinrich-Heine University, Germany

Leena Laasonen Helsinki Medical Imaging Center, University of Helsinki, Finland

Teemu Kantola Department of Anesthesiology, Helsinki University Central Hospital, Finland

Ari Ristimaki Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Department of Pathology, Helsinki University Central Hospital, Finland; Genome Scale Biology Program, Biomedicum Helsinki, Finland

Maria Rajecki Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland

Minna Oksanen Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland

Elina Haavisto Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland

Anna Kanerva Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland; Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland and

Timo Joensuu Docrates Oncology Hospital, Helsinki, Finland

Akseli Hemminki Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, FinlandCorrespondence[email protected]

show all

References

Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, . Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 2006;14:164–74.
PubMed Web of Science ®Google Scholar
Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101–17.
PubMedGoogle Scholar
Alemany R. A smart move against cancer for vaccinia virus. Lancet Oncol 2008;9:507–8.
PubMedGoogle Scholar
Prestwich R, Harrington K, Vile R, Melcher A. Immunotherapeutic potential of oncolytic virotherapy. Lancet Oncol 2008;9:610–2.
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Oncolytic adenovirus treatment of a patient with refractory neuroblastoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Oncolytic adenovirus treatment of a patient with refractory neuroblastoma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date